PRN: Global Pulmonary Arterial Hypertension (PAH) Drugs Market - Analysis, Technologies & Forecasts to 2021 - Increased Focus on Combination Therapies - Research and Markets

25/apr/2017 22:00:16 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Global Pulmonary Arterial Hypertension (PAH) Drugs Market - Analysis, Technologies & Forecasts to 2021 - Increased Focus on Combination Therapies - Research and Markets


DUBLIN, Apr. 25, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Pulmonary Arterial Hypertension (PAH) Drugs Market 2017-2021" report to their offering.

Research and Markets Logo

The global pulmonary arterial hypertension drugs market to grow at a CAGR of 3.2% during the period 2017-2021.

The report, Global Pulmonary Arterial Hypertension Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.

The latest trend gaining momentum in the market is increased focus on combination therapies. The PAH treatment is shifting toward the use of combination therapies that employ two or more drugs. A combination therapy with separate agents or a fixed dose of combination pill offers the maximum potential to lower blood pressure. The treatment is also aimed at targeting various disease mechanisms that may result in better outcome.

According to the report, one of the major drivers for this market is new disease-modifying therapies. Many new agents in the market are expected to show promising results in terms of efficacy as they target the receptors involved in the progression of PAH. For instance, OPSUMIT launched in 2013 in the US is an ERA, which mediates vasoconstriction, hypertrophy, and inflammation. The drug prevents the binding of endothelin (ET-1) to both endothelin receptors, ET-A and ET-B, resulting in decreased hypertension.

Key vendors

  • Actelion Pharmaceuticals
  • GlaxoSmithKline
  • Novartis
  • United Therapeutics

Other prominent vendors

  • AADi
  • Actelion Pharmaceuticals
  • Aires Pharmaceuticals
  • Arena Pharmaceuticals
  • Asklepion Pharmaceuticals
  • AstraZeneca
  • Bayer Healthcare
  • Berlin Cures
  • BIAL
  • DEKA Research & Development
  • Dong- A ST
  • Eiger BioPharmaceuticals
  • Gilead Sciences
  • Lung Biotechnology
  • Merck
  • Northern Therapeutics
  • Pfizer
  • PhaseBio Pharmaceuticals
  • Radikal Therapeutics
  • Reata Pharmaceuticals
  • SteadyMed Therapeutics
  • Velo Bio

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: An overview of PAH

PART 06: Pipeline analysis

PART 07: Market landscape

PART 08: Market segmentation by route of administration (RoA)

PART 09: Market segmentation by mechanism of action (MoA)

PART 10: Geographical segmentation

PART 11: Decision framework

PART 12: Drivers and challenges

PART 13: Market trends

PART 14: Vendor landscape

PART 15: Key vendor analysis

For more information about this report visit

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

blog comments powered by Disqus è un servizio offerto da Factotum Srl